Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson’s disease
暂无分享,去创建一个
T. Kon | T. Furukawa | M. Tomiyama | Takashi Nakamura | Chieko Suzuki | H. Nishijima | Iku Kinoshita | Yoshiki Murakami
[1] F. Manfredsson,et al. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats , 2022, Pharmacology Biochemistry and Behavior.
[2] C. Tanner,et al. Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease , 2022, NPJ Parkinson's disease.
[3] O. Rascol,et al. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. , 2022, Parkinsonism & related disorders.
[4] M. Tomiyama,et al. Morphological and Functional Changes of Striatal Neurons with L‐dopa‐induced Dyskinesia , 2021, Neurology and Clinical Neuroscience.
[5] W. Poewe,et al. Amantadine in the treatment of Parkinson's disease and other movement disorders , 2021, The Lancet Neurology.
[6] N. Inagaki,et al. Shootin1a-mediated actin-adhesion coupling generates force to trigger structural plasticity of dendritic spines. , 2021, Cell reports.
[7] P. Riederer,et al. Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials , 2021, Journal of Neural Transmission.
[8] N. Ichinohe,et al. GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming , 2020, Neurobiology of Disease.
[9] J. Kasahara,et al. Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism , 2019, Front. Neurol..
[10] S. Ueno,et al. Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease , 2018, Parkinson's disease.
[11] A. Crossman,et al. Animal models of l‐dopa‐induced dyskinesia in Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[12] C. Adler,et al. Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102 , 2018, Movement disorders clinical practice.
[13] T. Shirao,et al. The role of drebrin in dendritic spines , 2017, Molecular and Cellular Neuroscience.
[14] S. Ueno,et al. Levodopa treatment and dendritic spine pathology , 2017, Movement disorders : official journal of the Movement Disorder Society.
[15] W. Oertel,et al. Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3) , 2017, Movement disorders : official journal of the Movement Disorder Society.
[16] C. Tanner,et al. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial , 2017, JAMA neurology.
[17] H. Widner,et al. Memantine and reduced time with dyskinesia in Parkinson′s Disease , 2016, Acta neurologica Scandinavica.
[18] M. Bortolanza,et al. Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson’s Disease , 2016, Neurotoxicity Research.
[19] C. Tanner,et al. Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study) , 2015, Movement disorders : official journal of the Movement Disorder Society.
[20] M. Collu,et al. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease , 2014, Neuroscience.
[21] J. Yamada,et al. Morphologic changes of dendritic spines of striatal neurons in the levodopa‐induced dyskinesia model , 2014, Movement disorders : official journal of the Movement Disorder Society.
[22] A. Destée,et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease , 2014, Neurology.
[23] J. Yamada,et al. Drebrin immunoreactivity in the striatum of a rat model of levodopa‐induced dyskinesia , 2013, Neuropathology : official journal of the Japanese Society of Neuropathology.
[24] A. P. Valle,et al. Unexpected Improvement in Levodopa‐Induced Dyskinesia and On‐Off Phenomena After Introduction of Memantine for Treatment of Parkinson's Disease Dementia , 2013, Journal of the American Geriatrics Society.
[25] P. Ravenscroft,et al. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[26] M. Morari,et al. Amantadine attenuates levodopa‐induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels , 2011, Journal of neurochemistry.
[27] K. Hisanaga,et al. Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial , 2010, PloS one.
[28] E. Wolf,et al. Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[29] S. Varanese,et al. NMDA antagonist memantine improves levodopa‐induced dyskinesias and “On‐off” phenomena in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[30] K. Svoboda,et al. Experience-dependent structural synaptic plasticity in the mammalian brain , 2009, Nature Reviews Neuroscience.
[31] J. Jankovic. Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[32] M. Cenci,et al. Ratings of L‐DOPA‐Induced Dyskinesia in the Unilateral 6‐OHDA Lesion Model of Parkinson's Disease in Rats and Mice , 2007, Current protocols in neuroscience.
[33] W. Danysz,et al. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model , 2007, Behavioural Brain Research.
[34] Fabrizio Stocchi,et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. , 2005, Archives of neurology.
[35] C. Aoki,et al. Drebrin A is a postsynaptic protein that localizes in vivo to the submembranous surface of dendritic sites forming excitatory synapses , 2005, The Journal of comparative neurology.
[36] M. Murer,et al. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias , 2004, Behavioural Brain Research.
[37] E. Bézard,et al. Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson's Disease , 2004, Journal of Pharmacology and Experimental Therapeutics.
[38] T. Suda,et al. Amantadine increases l-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats , 2003, Brain Research.
[39] N. Wierup,et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease , 2002, The European journal of neuroscience.
[40] W. Poewe,et al. Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[41] S. Konitsiotis,et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. , 1999, Archives of neurology.
[42] T. Suda,et al. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. , 1999, Neuroreport.
[43] T. Chase,et al. Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys , 1998, Movement disorders : official journal of the Movement Disorder Society.
[44] A. Björklund,et al. L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA , 1998, The European journal of neuroscience.
[45] J. Brotchie,et al. Characterization of Enhanced Behavioral Responses tol-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease , 1998, Experimental Neurology.
[46] K. Shannon,et al. Amantadine and motor fluctuations in chronic Parkinson's disease. , 1987, Clinical neuropharmacology.
[47] M. Delong,et al. Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa , 2012, Neuropsychopharmacology.
[48] T. Archer,et al. Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice , 2009, Journal of Neural Transmission.
[49] M. Onofrj,et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. , 2004, Journal of neurology, neurosurgery, and psychiatry.